Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.
暂无分享,去创建一个
J. Morris | A. Goate | K. Mayo | Carlos Cruchaga | J. Norton | C. Graff | A. Hinrichs | Huei-Hsin Chiang | S. Bertelsen | Jun Wang | Noah Spiegel | J. Morris | J. Morris | H. Chiang
[1] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[2] A. Fagan,et al. SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease , 2010, PLoS genetics.
[3] Alzheimer's Disease Neuroimaging Initiative,et al. Validating predicted biological effects of Alzheimer's disease associated SNPs using cerebrospinal fluid biomarker levels , 2010, Alzheimer's & Dementia.
[4] Sudha Seshadri,et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.
[5] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[6] Jane S. Paulsen,et al. CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[7] Eden R Martin,et al. Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.
[8] M. J. Fresnadillo Martínez,et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions , 2010, Nature Genetics.
[9] Z. Arvanitakis. Update on Frontotemporal Dementia , 2010, The neurologist.
[10] N. Bresolin,et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease , 2009, Journal of the Neurological Sciences.
[11] P. Bosco,et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.
[12] K. Sleegers,et al. Serum biomarker for progranulin‐associated frontotemporal lobar degeneration , 2009, Annals of neurology.
[13] T. Bird. Progranulin plasma levels in the diagnosis of frontotemporal dementia. , 2009, Brain : a journal of neurology.
[14] A. Fagan,et al. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.
[15] R. Petersen,et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members , 2009, Brain : a journal of neurology.
[16] C. Graff,et al. Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family , 2008, Alzheimer's & Dementia.
[17] G. Binetti,et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration , 2008, Neurology.
[18] A. Fagan,et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.
[19] J. Morris,et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia , 2008, Human mutation.
[20] D. Stephan,et al. A survey of genetic human cortical gene expression , 2007, Nature Genetics.
[21] D. Geschwind,et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative , 2007, The Lancet Neurology.
[22] J. Morris,et al. Neuropathologic Heterogeneity in HDDD1: A Familial Frontotemporal Lobar Degeneration With Ubiquitin-positive Inclusions and Progranulin Mutation , 2007, Alzheimer disease and associated disorders.
[23] S. Melquist,et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.
[24] J. Morris,et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin , 2006, Annals of neurology.
[25] Joaquín Dopazo,et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes , 2006, Nucleic Acids Res..
[26] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[27] D. Thomas,et al. Case‐sibling gene‐association studies for diseases with variable age at onset , 2004, Statistics in medicine.
[28] M. Orozco,et al. Triplex-forming oligonucleotide target sequences in the human genome. , 2004, Nucleic acids research.
[29] Kenneth S. Kosik,et al. Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred , 2003 .
[30] Zuzana Dobbie,et al. Processing of gene expression data generated by quantitative real-time RT-PCR. , 2002, BioTechniques.
[31] Hongyu Zhao. Family-based association studies , 2000, Statistical methods in medical research.
[32] B Langholz,et al. Testing linkage disequilibrium in sibships. , 2000, American journal of human genetics.
[33] B. Tycko,et al. No association between a presenilin 1 polymorphism and Alzheimer disease. , 2000, Archives of neurology.
[34] Steven M. Horvath,et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.
[35] J. Morris. The Clinical Dementia Rating (CDR) , 1993, Neurology.
[36] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[37] A. Fagan,et al. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. , 2010, Journal of Alzheimer's disease : JAD.
[38] G. Bedoya,et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. , 2003, Annals of neurology.